Intellipharmaceutics International Inc. Overview
Pro stress-test →Intellipharmaceutics specializes in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals.
Strategic Profile
Pro stress-test →The company has developed several drug delivery systems based on its technology platform, with a pipeline of products in various stages of development, including ANDA and NDA 505(b)(2) drug product candidates. Products target therapeutic areas including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
Competitive Landscape
Pro stress-test →Competitors include BioDelivery Sciences International, Collegium Pharmaceutical, and Acura Pharmaceuticals. Intellipharmaceutics competes in the specialty generic and controlled-release pharmaceutical space, where larger pharma companies and established generic manufacturers hold significant market share advantages.
Industry Context
Intellipharmaceutics International Inc. operates in Specialty pharmaceutical drug delivery systems.
Key facts
Founded: Unknown · Headquarters: Toronto, Canada · Employees: Unknown · Revenue: $905K (TTM as of August 2023) · Market cap: N/A